R
Response Biomedical
Acute care diagnostic systems delivering lab-quality results within minutes, customizable and maintenance-free
About Response Biomedical
Response Biomedical is a company specializing in acute care diagnostic solutions. Their primary product, the RAMP system, offers rapid, quantitative, and self-calibrating diagnostic tests that deliver central lab-quality results within minutes. The company serves healthcare providers who require quick and accurate diagnostic results to make better and faster decisions. Operating in the acute care diagnostics market, Response Biomedical's RAMP systems are used for a variety of tests including cardiovascular, infectious disease, sepsis, women's health, arbovirus, and biodefense. The business model revolves around selling these diagnostic systems and the associated tests, generating revenue through the sale of both the hardware and consumables. The RAMP systems are designed to be plug-and-play, easy to use, and do not require maintenance or service contracts, making them a cost-effective solution for healthcare providers. Additionally, the company offers 24-hour technical support to ensure seamless operation for its clients.
Source: Dealroom company dataAt a glance
- Status
- Listed
- Founded
- 1992
- Headquarters
- Vancouver, Canada
- Listing
- IPO 2003
- Sector
- Biotech & Life Sciences
Knowledge graph
More headlines
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series B and later1 investor entered at this stage
Standard Treasury
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Response Biomedical on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Response Biomedical on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.